Presentation Resources
-ASAM definition for addiction
https://www.asam.org/quality-care/definition-of-addiction
-What is Medication-Assisted Treatment
https://www.samhsa.gov/medications-substance-use-disorders
-Unobserved "home" induction onto buprenorphine2014 Sep-Oct;8(5):299-308. doi: 10.1097/ADM.0000000000000059. Abstract Only-https://pubmed.ncbi.nlm.nih.gov/25254667/
-Cunningham, C. O., Giovanniello, A., Li, X., Kunins, H. V., Roose, R. J., & Sohler, N. L. (2011). A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. Journal of substance abuse treatment, 40(4), 349–356. doi:10.1016/j.jsat.2010.12.002 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081891/
-Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA; American Society Of Addiction Medicine. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction (open access)
J Addict Med. 2011 Dec;5(4):254-63. doi:10.1097/ADM.0b013e3182312983
https://journals.lww.com/journaladdictionmedicine/fulltext/2011/12000/statement_of_the_american_society_of_addiction.3.aspx
-Alford, D. P., LaBelle, C. T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J. H. (2011). Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Archives of internal medicine, 171(5), 425–431. doi:10.1001/archinternmed.2010.541 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/226781
-Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Cochrane Systematic Review - Intervention Version published: 06 February 2014 see https://doi.org/10.1002/14651858.CD002207.pub4 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002207.pub4/full
-NIDA (2016). Understanding Drug Abuse and Addiction: What Science Says. Retrieved January 2, 2017,
https://nida.nih.gov/sites/default/files/1921-understanding-drug-abuse-and-addiction-what-science-says.pdf
-Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence (summary) . Cochrane Systematic Review - Intervention Version published: 05 October 2011. https://doi.org/10.1002/14651858.CD004147.pub
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004147.pub4/full
-Schwartz, R. P., Gryczynski, J., O'Grady, K. E., Sharfstein, J. M., Warren, G., Olsen, Y., … Jaffe, J. H. (2013). Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. American journal of public health, 103(5), 917–922. doi:10.2105/AJPH.2012.301049
https://ajph.aphapublications.org/doi/10.2105/AJPH.2012.301049
-Sustained-release naltrexone for opioid dependence Apr 16;(2):CD006140. doi: 10.1002/14651858.CD006140.pub2.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006140.pub2/full
-Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Jr, … O'Brien, C. P. (2016). Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. The New England journal of medicine, 374(13), 1232–1242. doi:10.1056/NEJMoa1505409
https://www.nejm.org/doi/10.1056/NEJMoa1505409
-Krupitsky E1, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60358-9/fulltext
-LaBelle, C. T., Han, S. C., Bergeron, A., & Samet, J. H. (2016). Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers. Journal of substance abuse treatment, 60, 6–13. doi:10.1016/j.jsat.2015.06.010
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682362/
-Simpatico, T.A., Vermont responds to its opioid crisis, Abstract only.
https://pubmed.ncbi.nlm.nih.gov/25869219/
-Lim, J. K., Bratberg, J. P., Davis, C. S., Green, T. C., & Walley, A. Y. (2016). Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists. Journal of addiction medicine, 10(5), 300–308. doi:10.1097/ADM.0000000000000223
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049966/
-SAMHSA-Medication Assisted Treatment Resources
https://www.samhsa.gov/medications-substance-use-disorders/training-resources
-SAMHSA-Medication for the treatment of Alcohol use disorder-Pocket Guide
https://eguideline.guidelinecentral.com/i/1254278-alcohol-withdrawal-management/1?
-1-year retention and social function after buprenorphine assisted relapse prevention treatment for heroin dependence in sweden. Abstract only https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)12600-1/fulltext
Related Resources:
Opioid Prescribing for Chronic Pain — Achieving the Right Balance through Education
https://www.nejm.org/doi/10.1056/NEJMp1512932-
https://www.sciencedaily.com/releases/2016/01/160128074333.htm